Home >> Marketplace Archives >> CPO assay gets CE mark, 3/18

CPO assay gets CE mark, 3/18

Print Friendly, PDF & Email


March 2018—Becton Dickinson and Check-Points obtained the CE mark for a next-generation molecular screening test for antibiotic-resistant carbapenemase-producing organisms on the BD Max System.

The BD Max Check-Points CPO assay provides detection of the five most common carbapenemase genes—Klebsiella pneumoniae carbapenemase (KPC), New Delhi metallo-β-lactamase (NDM), oxacillin-hydrolyzing β-lactamase-48 (OXA-48, including OXA-181), Verona integron-encoded metallo-β-lactamase (VIM), and imipenem-hydrolyzing β-lactamase (IMP)—in less than 2.5 hours. Early detection of patients colonized with these organisms can provide the necessary information to implement proper infection control measures.

This assay replaces an earlier version of the test from Check-Points and offers an improved workflow and an additional target (IMP).

BD, 201-847-6800

Check-Points, +31 (0)317 453 908


Check Also

BD HPV assay gets premarket approval

March 8, 2018—Becton Dickinson received premarket approval from the FDA for the BD Onclarity HPV...